Sirolimus- and Paclitaxel-Coated Balloons Deliver Comparable 1-Year PCI Outcomes

Why It Matters

The findings suggest that clinicians can consider SCBs as a viable alternative to PCBs without sacrificing safety or efficacy, potentially expanding therapeutic options for coronary lesions. This parity may influence device adoption strategies and reimbursement decisions across cardiology markets.

Key Takeaways

• Study includes >8,000 PCI patients from 2022‑2025
• PCBs showed lower in‑stent restenosis than SCBs
• One‑year outcomes: no difference in mortality or repeat PCI
• Non‑randomized design and imbalance in cohort sizes limit causality

Pulse Analysis

Drug‑coated balloons have reshaped the treatment of coronary artery disease by delivering antiproliferative agents directly to the vessel wall, avoiding permanent stent implantation. Paclitaxel‑coated balloons have dominated the market for years, but emerging sirolimus formulations promise similar drug‑release kinetics with potentially improved safety profiles. Prior head‑to‑head trials were small and often compared a single brand of each technology, leaving clinicians uncertain about real‑world performance across diverse devices.

The Swedish SCAAR registry analysis pooled data from over 7,500 PCB procedures and more than 500 SCB cases, encompassing seven PCB and three SCB platforms. Although PCBs modestly reduced in‑stent restenosis, the study observed no statistically significant differences in target‑segment revascularization, myocardial infarction, repeat PCI, or all‑cause mortality at one year. These outcomes held true for both de‑novo lesions and in‑stent restenosis, underscoring the robustness of the findings despite the observational design. However, the lack of randomization and the disproportionate sample sizes mean causality cannot be definitively established.

For the interventional cardiology market, the parity in one‑year outcomes could accelerate the adoption of sirolimus‑coated balloons, especially as manufacturers refine delivery systems and seek regulatory approvals in the United States. Payers may view SCBs as a cost‑effective alternative, potentially reshaping reimbursement models that have traditionally favored paclitaxel devices. Future randomized trials will be essential to confirm these observational results, but the current evidence already signals a broader therapeutic toolkit for clinicians managing complex coronary lesions.